{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/balanitis/prescribing-information/topical-imidazoles/","result":{"pageContext":{"chapter":{"id":"7db80726-7da5-5db6-85b2-e6a211cd3278","slug":"topical-imidazoles","fullItemName":"Topical imidazoles","depth":2,"htmlHeader":"<!-- begin field 4c8f94ae-9b51-4c20-9e8e-911ec6282e06 --><h2>Topical imidazoles</h2><!-- end field 4c8f94ae-9b51-4c20-9e8e-911ec6282e06 -->","summary":"","htmlStringContent":"<!-- begin item 87777fe8-2c35-43ec-a117-b2034eac44ed --><!-- end item 87777fe8-2c35-43ec-a117-b2034eac44ed -->","topic":{"id":"4da8d9db-f350-588f-83e8-f5efc3335305","topicId":"eb6c6cd9-3331-4790-a1f9-a11ed643b2b0","topicName":"Balanitis","slug":"balanitis","lastRevised":"Last revised in October 2018","chapters":[{"id":"cf843687-5035-5956-aa14-3d8bacbd404f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"41d01ca1-763c-529e-8026-28dd85d36b16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b9dae5ef-34a6-57ed-bf21-9b9543370ecd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2fc17559-2630-5868-aeda-16c7394d8223","slug":"changes","fullItemName":"Changes"},{"id":"699e0434-3685-5acc-9956-84bc269b6ae0","slug":"update","fullItemName":"Update"}]},{"id":"e0b4a9d5-30c1-589c-b52c-49a537ed88cf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"045bf9d9-1913-57d7-85ac-7dd14d9a6ad1","slug":"goals","fullItemName":"Goals"},{"id":"9242a4e0-3dd3-598a-8015-c1fd35c8ae24","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8d94eba3-36ae-5c38-b3bd-c6fe5a1d1122","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c3fec0e-6d36-590b-a67a-9fde96b588b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd19254a-f9ef-5cd1-af7b-f5226c2474da","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5cc7acd3-6e1c-5b23-9f58-aa1a50f67faa","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"10c99e35-8476-5d3d-a309-c80fc5ed5fa7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e615c22a-91ed-5f2c-8d1b-657c4409d5ff","slug":"definition","fullItemName":"Definition"},{"id":"93cf765a-7e94-5ba7-bc6c-d001406aa393","slug":"causes","fullItemName":"Causes"},{"id":"8f5ac951-0e46-5c89-9a50-27eb3f65076f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"feeb11e3-9d66-5d96-a507-c526af44a7f0","slug":"complications","fullItemName":"Complications"}]},{"id":"fb758dfb-b24b-5875-9570-5d6b29ad0606","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7f4b11b8-626e-56eb-9a8d-5aafbb365797","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e0d6dde7-d713-5601-94f9-9a443f7c7cb3","slug":"assessment","fullItemName":"Assessment"},{"id":"a1bd5ccf-b828-59e7-893c-ab9d9e755750","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"de355ac0-0522-5d92-a913-4694aa861fd7","fullItemName":"Management","slug":"management","subChapters":[{"id":"bd1e001e-c6a9-5d54-88ca-ce4a56b46edd","slug":"balanitis-children","fullItemName":"Scenario: Balanitis - children"},{"id":"44e5d982-e2af-5996-ab20-fcc33b89adf1","slug":"balanitis-adults","fullItemName":"Scenario: Balanitis - adults"}]},{"id":"3fdc0cf3-e98c-5a04-9525-c21e93db6dad","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"7db80726-7da5-5db6-85b2-e6a211cd3278","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"ad41f201-03ec-5da9-ac6a-1902fa6cad6c","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"29db55e2-6292-57cc-bb96-e0331bea331b","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"41cf5c1f-073b-55f6-bca1-f483e1e31783","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"e2c0e955-b610-5ee0-83a7-020247e8d2e3","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"8384c8ca-522a-546a-971b-71a12dc40ba9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1946dc01-8848-5119-a228-39e16c9c2fee","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a80a505e-c0ca-5472-966a-cfb4d225c502","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f260f355-769f-5d83-8c42-f5b606d7cab7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bedff117-4d2b-5b3b-ae77-431100374dfe","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ccf2a0ba-1a8a-5d6c-829c-a90817d3a0cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c09916ae-40e4-5285-8ce4-a0995eb5225b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"fcdbbdd1-c423-5b0c-b610-1ba72cc625c9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3fdc0cf3-e98c-5a04-9525-c21e93db6dad","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6be347e5-71cf-5825-8395-384da0f6318a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 33ca3d0a-d52b-4d93-9a8a-a87401680fae --><h3>Contraindications and cautions</h3><!-- end field 33ca3d0a-d52b-4d93-9a8a-a87401680fae -->","summary":"","htmlStringContent":"<!-- begin item c56a5644-2ff1-4443-b17f-a8740168023e --><!-- begin field b57cf2a3-eb4f-4cb9-8864-a87401680fae --><p><strong>Inform the person that when using topical imidazoles:</strong></p><ul><li>Avoid contact with the eyes and mucous membranes.</li><li>Clotrimazole may cause damage to latex condoms, reducing their effectiveness. Advise the use of alternative contraception for at least five days after using this preparation.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">BNF 74, 2017</a>] </p><!-- end field b57cf2a3-eb4f-4cb9-8864-a87401680fae --><!-- end item c56a5644-2ff1-4443-b17f-a8740168023e -->","subChapters":[]},{"id":"7bfc5dc4-e348-592f-99ff-c7f1028ade49","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 05590be6-7133-460e-805a-a874016875f8 --><h3>Adverse effects</h3><!-- end field 05590be6-7133-460e-805a-a874016875f8 -->","summary":"","htmlStringContent":"<!-- begin item 5537b389-9245-4685-b960-a874016873aa --><!-- begin field a8635c03-b618-42d3-9884-a874016875f8 --><p><strong>Topical imidazoles are generally well tolerated. Possible adverse effects include:</strong></p><ul><li>Local skin irritation, rash, erythema, itch, mild burning sensation, and hypersensitivity reactions. Treatment should be discontinued if these are severe.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">BNF 74, 2017</a>] </p><!-- end field a8635c03-b618-42d3-9884-a874016875f8 --><!-- end item 5537b389-9245-4685-b960-a874016873aa -->","subChapters":[]},{"id":"81b89980-2330-501d-999d-e00b872da0de","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field bb4a894a-b2cd-44e2-9001-a87401689951 --><h3>Drug interactions</h3><!-- end field bb4a894a-b2cd-44e2-9001-a87401689951 -->","summary":"","htmlStringContent":"<!-- begin item 6be22f39-6594-44c6-82c0-a874016896f4 --><!-- begin field d427ec55-e070-4ae2-8471-a87401689951 --><p><strong>Possible drug interactions with topical imidazoles include:</strong></p><ul><li>Oral miconazole and econazole are known to inhibit CYP450 enzymes, but due to the limited systemic availability of topical preparations, clinically relevant interactions are rare.<ul><li>The effect of oral anticoagulants (such as warfarin) may be enhanced by topical miconazole or econazole. Monitor the person’s international normalised ratio (INR) during concurrent use of topical miconazole or econazole with an oral anticoagulant, and adjust the warfarin dose accordingly.</li></ul></li><li>There are no known significant drug interactions with topical clotrimazole or ketoconazole.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI, 2015b</a>] </p><!-- end field d427ec55-e070-4ae2-8471-a87401689951 --><!-- end item 6be22f39-6594-44c6-82c0-a874016896f4 -->","subChapters":[]},{"id":"1f02f94e-7b9b-599f-a0de-19ee771a7801","slug":"application-regimens","fullItemName":"Application regimens","depth":3,"htmlHeader":"<!-- begin field eb659b26-c5f7-42a4-8bc8-a87701627986 --><h3>Application regimens</h3><!-- end field eb659b26-c5f7-42a4-8bc8-a87701627986 -->","summary":"","htmlStringContent":"<!-- begin item d5ab3f8f-2d7c-4f69-9ac4-a87701627610 --><!-- begin field 19f1a3cf-bce6-4a48-816b-a87701627986 --><ul><li>Topical clotrimazole 1% is licensed for the treatment of balanitis.<ul><li>Advise the person to apply topical clotrimazole to the affected area 2 to 3 times daily for at least two weeks.</li></ul></li><li>Topical miconazole 2% is licensed for treatment of mycotic infections of the skin and nails.<ul><li>Advise the person to apply topical miconazole to the affected area twice daily. Treatment should be continued for 10 days after lesions have healed.</li></ul></li><li>Topical econazole 1% is licensed for the treatment of mycotic balanitis.<ul><li>Advise the person to apply topical econazole to the affected area twice daily for at least two weeks.</li></ul></li><li>Topical ketoconazole 2% is licensed for the treatment of fungal infections of the skin.<ul><li>Advise the person to apply topical ketoconazole to the affected area once or twice daily. Treatment should be continued for a few days after the lesions have disappeared.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">BNF 74, 2017</a>]</p><!-- end field 19f1a3cf-bce6-4a48-816b-a87701627986 --><!-- end item d5ab3f8f-2d7c-4f69-9ac4-a87701627610 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}